Sign in

Hannes Becker

@hannes-becker1996.bsky.social
47 followers 81 following 6 posts

🧑‍🔬🧫🧑‍⚕️Clinician Scientist @NeuroOncoTue.bsky.social 🧠🏥Neurosurgical Resident @University Hospital Tuebingen

PostsRepliesMedia
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 22/05/2026
We are very happy to present you our work, recently accepted in Neurooncology! @ghtabatabai.bsky.social @hih-tuebingen.bsky.social academic.oup.com/neuro-oncolo...
academic.oup.com
Molecular modulators of CDK4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening
AbstractBackground. Glioblastoma harbors frequent alterations in the retinoblastoma (RB1) pathway, providing a genetic rationale for therapeutic targeting
033
Hannes Becker @hannes-becker1996.bsky.social · 14/11/2025
Very happy to had the opportunity to present our data at the DGN in Berlin. @ghtabatabai.bsky.social @hih-tuebingen.bsky.social @dgn-ev.bsky.social
022
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 21/10/2025
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions! Looking forward to Rome! @eanoassociation.bsky.social @ghtabatabai.bsky.social @hannes-becker1996.bsky.social @nihalolcaydogan.bsky.social @hih-tuebingen.bsky.social
0105
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 18/10/2025
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma! @eanoassociation.bsky.social @ghtabatabai.bsky.social @hih-tuebingen.bsky.social
094
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 18/10/2025
Great talk by @ghtabatabai.bsky.social about time management in academia @eanoassociation.bsky.social
052
Hannes Becker @hannes-becker1996.bsky.social · 17/10/2025
Glad to have the opportunity to present our data! @eanoassociation.bsky.social
020
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 17/10/2025
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social @hannes-becker1996.bsky.social @ghtabatabai.bsky.social
032
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 17/10/2025
Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen. More to come! @eanoassociation.bsky.social
052
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 29/09/2025
Extremely happy that we could have contributed!
011
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 29/09/2025
Innovative trial design, thank you for the opportunity for being part of it!
011
Reposted by Hannes Becker
EANO @eanoassociation.bsky.social · 24/09/2025
🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice. 🔗 academic.oup.com/neuro-oncolo...
02910
Reposted by Hannes Becker
EANO @eanoassociation.bsky.social · 09/09/2025
🧠 The phase 1/2 N2M2 umbrella trial lead by former EANO president @wickwolfgang.bsky.social has just been published in Nature Medicine 🔗 www.nature.com/articles/s41... #NeuroOncology #EANOessentials #BrainTumors #CancerResearch
nature.com
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial - Nature Medicine
In a phase 1/2a umbrella trial in patients with glioblastoma matching targeted therapies according to tumor molecular profiling, temsirolimus plus radiotherapy improved PFS compared to standard of car...
0134
Hannes Becker @hannes-becker1996.bsky.social · 03/06/2025
Glad to present our data at this years #DGNC2025
020
Reposted by Hannes Becker
Neurooncology Tuebingen @neurooncotue.bsky.social · 03/06/2025
Thank you for having the opportunity to present our data at this year DGNC in Hanover. #DGNC2025
041
Reposted by Hannes Becker
Ghazaleh Tabatabai @ghtabatabai.bsky.social · 20/04/2025
Almost 25 year old T-shirt, reminds me of great experience at MGH/HMS 2000/2001, @harvard.edu - hard to see this institution under pressure now, and impressed by the integrity and resilience of Harvard leadership (more on LinkedIn) 🙌 #Harvard #AcademicFreedom #ScienceForDemocracy #ScienceMatters
0113
Reposted by Hannes Becker
Luisa Neubauer @luisaneubauer.bsky.social · 23/02/2025
Hoffnung fällt nicht vom Himmel. Hoffnung ist harte Arbeit. Heute, morgen, übermorgen. Wir sind da. Und wir sind viele.
472189342
Reposted by Hannes Becker
Hertie-Institut für klinische Hirnforschung (HIH) @hih-tuebingen.bsky.social · 21/02/2025
Thank you for your engagement Ghazaleh Tabatabai 🙏 #aufstehenfuerdemokratie
0106
Hannes Becker @hannes-becker1996.bsky.social · 20/02/2025
#aufstehenfuerdemokratie
010
Reposted by Hannes Becker
Ghazaleh Tabatabai @ghtabatabai.bsky.social · 12/02/2025
Tübingen 12 Feb 2025 Geschwister Scholl Platz Democracy needs facts Science needs Democracy. #aufstehenfuerdemokratie
0125
Reposted by Hannes Becker
Winkler Laboratory @winklerlab.bsky.social · 07/02/2025
📢 Es ist 5 vor 12❗ "Aufstehen für Demokratie" setzt sich für faktenbasierte politische Entscheidungen und Demokratie ein: www.aufstehenfuerdemokratie.de www.openpetition.de/!ychtb 📅 Sei dabei am 12.02 um 11:55 Uhr an Hochschulen und Forschungseinrichtungen 🔬 Wissenschaft braucht Demokratie 🤝
0135
Hannes Becker @hannes-becker1996.bsky.social · 16/01/2025
Great to see this finally out😍 Glad that I could contribute to this exciting Story! @hih-tuebingen.bsky.social @unituebingen.bsky.social
050
Hannes Becker @hannes-becker1996.bsky.social · 07/01/2025
Happy that I could contribute to this fantastic work! Check it out😉
050
Reposted by Hannes Becker
International Consortium on Meningiomas (ICOM) @icomeningioma.bsky.social · 16/12/2024
@ghtabatabai is a neurologist and a physician scientist at the University of Tübingen and the Managing Director Neurology at the University Hospital Tübingen. Her research includes target discovery & validation, molecular mechanisms of treatment resistance, & novel delivery routes to brain tumors.
Member Spotlight: Dr. Ghazaleh Tabatabai
074